Fundraise / allotmentFiled on BSE ·
Krsnaa Diagnostics receives NSE in-principle approval for issue of 16.21 lakh shares
Krsnaa Diagnost. · Healthcare Services
What the filing says
- NSE granted in-principle approval on October 8, 2026, for 16,21,000 equity shares of ₹5 each, convertible from warrants issued on preferential basis
- Approval subject to conditions including filing listing application, obtaining statutory approvals, and compliance with SEBI LODR, Companies Act, and other laws
- Company advised to strengthen internal controls and obtain undertaking from allottees to avoid trading violations before allotment; NSE reserves right to withdraw approval if information is incomplete or misleading
Original filing
Announcement Under Regulation 30 Of SEBI (LODR) Reg, 2015
Read the filing on BSE (PDF) →Companies guiding to strong growth
Ranked by management's own guidance on revenue and margins — not by us.
Waaree Energies
Electrical Equipment
Revenue growth 40%+Margin up 2%+
Sign up free to see all 6 →
See full rankingsRank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
More from Krsnaa Diagnost.
Other fundraise / allotment filings this fortnight
- Fundraise / allotmentMIC Electronics LtdEbisu Global Opportunities Fund Limited acquires shares in MIC Electronics Limited
- Fundraise / allotmentBhagyanagar India LtdBhagyanagar India Limited allotment of shares by Tieramet Limited after demerger
- Fundraise / allotmentSuryoday Small Finance Bank LtdSuryoday Small Finance Bank allots ₹200 crore subordinate NCDs on private placement
- Fundraise / allotmentSMC Global Securities LtdSMC Global Securities to discuss Preferential Warrant Issuance on Oct 14, 2026
- Fundraise / allotmentEmbassy Developments LtdEmbassy Developments Limited credit rating upgraded to IVR A/Stable on Oct 9, 2026
- Fundraise / allotmentCanara HSBC Life Insurance Company LtdCanara HSBC Life Insurance Ltd reports Q2 FY2026-27 financials and board actions
Summary written by Arthneeti from the company's filing with the stock exchange; check the original filing for full details. Arthneeti is a research and analytics platform, not a SEBI-registered investment adviser, and nothing here is a recommendation to buy or sell.